Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

35.64USD
18 May 2018
Change (% chg)

$-0.07 (-0.20%)
Prev Close
$35.71
Open
$35.58
Day's High
$35.74
Day's Low
$35.43
Volume
4,743,555
Avg. Vol
7,768,318
52-wk High
$39.43
52-wk Low
$31.67

Select another date:

Thu, May 17 2018

BRIEF-Trial shows Pfizer's Lyrica reduces seizures in children with epilepsy

* LYRICA® (PREGABALIN) ORAL SOLUTION CV PHASE 3 TRIAL IN PEDIATRIC EPILEPSY MEETS PRIMARY ENDPOINT

BRIEF-Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA

* PFIZER’S BIOSIMILAR RETACRIT® (EPOETIN ALFA-EPBX) APPROVED BY U.S. FDA

Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

UPDATE 2-Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

* Shares of Amgen, JNJ fall in afternoon trading (Adds analyst comments, updates shares)

FDA approves Pfizer's biosimilar of Amgen's Epogen

May 15 The U.S. Food and Drug Administration on Tuesday approved Pfizer Inc's biosimilar of Amgen Inc's anemia treatment Epogen.

BRIEF-Xtalpi Says Research Collaboration With Pfizer To Develop Artificial Intelligence-Powered Software Platform

* XTALPI INC - STRATEGIC RESEARCH COLLABORATION WITH PFIZER TO DEVELOP A HYBRID PHYSICS- AND ARTIFICIAL INTELLIGENCE-POWERED SOFTWARE PLATFORM Source text for Eikon: Further company coverage:

BRIEF-Pfizer Says Shareholder Proposal Regarding Independent Chair Policy Not Approved By Shareholders

* PFIZER SAYS SHAREHOLDER PROPOSAL REGARDING INDEPENDENT CHAIR POLICY NOT APPROVED BY SHAREHOLDERS IN ANNUAL MEETING ON APRIL 26, 2018 Source text for Eikon: (http://bit.ly/2jn0cJS) Further company coverage:

US STOCKS-Wall St falls as cost pressures rise, oil prices retreat

* Indexes down: Dow 1.1 pct, S&P 0.53 pct, Nasdaq 0.06 pct (Updates to early afternoon)

Pfizer first-quarter results miss estimates as key drug sales fall short

NEW YORK Pfizer Inc on Tuesday reported lower-than-expected first-quarter revenue as demand for some key drugs and international sales fell short of estimates, sparking a 5.1 percent drop in shares of the largest U.S. drugmaker. | Video

UPDATE 4-Pfizer 1st-qtr results miss estimates as key drug sales fall short

NEW YORK, May 1 Pfizer Inc on Tuesday reported lower-than-expected first-quarter revenue as demand for some key drugs and international sales fell short of estimates, sparking a 5.1 percent drop in shares of the largest U.S. drugmaker.

Select another date: